Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1895-1902

  Aguilar, Cristina ^a   Aguilar, Cecilia ^a   Lopez Marure, Rebeca ^b   Jiménez SÁNCHEZ, Alejandro ^a   Rocha Zavaleta, Leticia ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

c Kit; Cell migration; Cervical cancer; Erythropoietin; Stem cell factor

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT5 PROTEIN; STEM CELL FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL MIGRATION; CELL SURVIVAL; CERVICAL CANCER CELL LINE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; METASTASIS; UTERINE CERVIX CANCER; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STEM CELL FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 84899498407     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2044     Document Type: Article

References (35)

1. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O and Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236, 1993. (Pubitemid 23221699)
2. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A and Sawyer ST: Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 93: 3757-3773, 1999. (Pubitemid 29249822)
3. Sokolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C and Lodish HF: Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98: 3261-3273, 2001.
4. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL and Krystal G: Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell prolif-eration and Stat5 activation. EMBO J 14: 5557-5568, 1995.
5. Blume-Jensen P, Janknecht R and Hunter T: The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8: 779-782, 1998. (Pubitemid 28301165)
6. Krystal GW, DeBerry CS, Linnekin D and Litz J: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family inhibitor PP1. Cancer Res 58: 4660-4666, 1998. (Pubitemid 28480632)
7. Sundström M, Alfredsson J, Olsson N and Nilsson G: Stem cell factor-induced migration of mast cells requires p38 mitogen-activated protein kinase activity. Exp Cell Res 267: 144-151, 2001. (Pubitemid 32579150)
8. Maddens S, Charruyer A, Plo I, Dubreuil P, Berger S, Salles B, Laurent G and Jaffrézou JP: Kit signalling inhibits the sphingo-myelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. Blood 100: 1294-1301, 2002. (Pubitemid 34864284)
9. Trieselmann NZ, Soboloff J and Berger SA: Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 60: 759-766, 2003. (Pubitemid 36570766)
10. Wu H, Klingmüller U, Besmer P and Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377: 242-246, 1995.
11. Wu H, Klingmüller U, Acurio A, Hsiao JG and Lodish HF: Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci USA 94: 1806-1810, 1997. (Pubitemid 27113917)
12. Hong L, Ramdas B, Chen J, Harris C, Wojchowski DM and Kapur R: KIT associated intracellular tyrosines play an essential role in EpoR co-signalling. Cell Signal 20: 1513-1520, 2008.
13. Farrell F and Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 (Suppl 5): 18-30, 2004. (Pubitemid 39658342)
14. Horie K, Fujita J, Takakura K, Kanzaki H, Suginami H, Iwai M, Nakayama H and Mori T: The expression of c-kit protein in human adult and fetal tissues. Hum Reprod 8: 1955-1962, 1993. (Pubitemid 23337165)
15. Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A and Chow T: Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer 16: 752-756, 2006.
16. Caceres-Cortes JR, Alvarado-Moreno JA, Waga K, Rangel-Corona R, Monroy-Garcia A, Rocha-Zavaleta L, Urdiales-Ramos J, Weiss-Steider B, Haman A, Hugo P, et al: Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res 61: 6281-6289, 2001. (Pubitemid 32762568)
17. Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine erythro-poietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer 129: 2566-2576, 2011.
18. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G and Verma A: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7: 537-543, 2005. (Pubitemid 40791872)
19. Lester RD, Jo M, Campana WM and Gonias SL: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280: 39273-39277, 2005. (Pubitemid 41713881)
20. Hamadmad SN and Hohl RJ: Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther 324: 1227-1233, 2008. (Pubitemid 351397840)
21. Fraser JK, Lin FK and Berridge MV: Expression and modulation of specific, high affinity binding sites for erythropoietin on the human erythroleukemic cell line K562. Blood 71: 104-109, 1988. (Pubitemid 18050398)
22. Fujisue Y, Nakagawa T, Takahara K, Inamoto T, Kiyama S, Azuma H and Asahi M: Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines. Oncol Lett 5: 1765-1770, 2013.
23. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G and Xu X: Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 31: 1649-1660, 2012.
24. Steinmann K, Richter AM and Dammann RH: Epigenetic silencing of erythropoietin in human cancers. Genes Cancer 2: 65-73, 2011.
25. Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ and Feldman L: An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 7: 1150-1157, 2009.
26. Inoue M, Kyo S, Fujita M, Enomoto T and Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 54: 3049-3053, 1994. (Pubitemid 24187794)
27. Kapur R, Cooper R, Zhang L and Williams DA: Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signalling pathways. Blood 97: 1975-1981, 2001. (Pubitemid 32239076)
28. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, Breese R, Marshall M, Dinauer MC and Williams DA: Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 12: 557-568, 2000.
29. Fraser L, Taylor AH and Forrester LM: SCF/KIT inhibition has a cumulative but reversible effect on the self-renewal of embryonic stem cells and on the survival of differentiating cells. Cell Reprogram 15: 259-268, 2013.
30. Liu L, Zhang X, Do C, Zhang X, Hou N, Zhao D, Sun J, Li L, Wang X and Ma C: MEK1-independent activation of MAPK and MEK1-dependent activation of p70 S6 kinase by stem cell factor (SCF) in ovarian cancer cells. Biochem Biophys Res Commun 382: 385-389, 2009.
31. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G and Rodeck U: Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 61: 2200-2206, 2001. (Pubitemid 32692048)
32. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 8: 615-626, 2010.
33. Wu H, Klingmüller U, Bersmer P and Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377: 242-246, 1995.
34. Grebier F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, et al: Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood 111: 4511-4522, 2008.
35. Sui X, Krantz SB, You M and Zhao Z: Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92: 1142-1149, 1998. (Pubitemid 28369026)